BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological ...
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical ...
CALGARY, Alberta, Oct. 17, 2024 (GLOBE NEWSWIRE) -- ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), ...
The gross proceeds from the offering are expected to be approximately $3.13 million, excluding any proceeds that may be received upon exercise of the warrants and before deducting the placement ...
Bioscience Corp. (Nasdaq:LEXX; LEXXW), a developer of drug delivery platforms, today announced that it has closed a ...
Information on the total number of voting rights and sharesGhent, BELGIUM, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Press Release Regulated information (Euronext Brussel : BTLS) (the “Company” or “Biotalys” ...
Information on the total number of voting rights and sharesGhent, BELGIUM, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Press Release Regulated information Biotalys NV) (the "Company" or "Biotalys"), an ...
The proceeds from both the public offering and private placement are earmarked for general ... and Exchange Commission (SEC), including a base prospectus and a prospectus supplement related ...
The Company will use the proceeds of the Offering to fund the advancement of the Company's Preliminary Economic Study on its wholly owned 100% owned high-grade Perron Gold Project and general working ...
The company plans to use the proceeds to support exploration at the Lunahuasi project in Argentina and the Los Helados ...
Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 - Prospectus Exemptions ("NI ... the Company announces a concurrent non-brokered private ...
The offering is being made only by means of a prospectus which is a part of the effective registration statement. The warrants will be issued in a concurrent private placement. A final prospectus ...